|Videos|June 18, 2015
Hepatitis C: Short Term Drug Costs Versus Long Term Care Costs
Author(s)Davy James, Managing Editor
Marc O'Connor, Chief Operating Officer of Curant Health, discusses how to evaluate the short term cost of treatment with new hepatitis C drugs versus the long term cost of care.
Advertisement
Marc O'Connor, Chief Operating Officer of Curant Health, discusses how to evaluate the short term cost of treatment with new hepatitis C drugs versus the long term cost of care.
This video was recorded courtesy of Armada Health Care at the 2015 Armada Specialty Pharmacy Summit in Las Vegas, Nevada.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves First At-Home Treatment Device for Depression
2
Integrated Specialty Pharmacy Services Improve Speed to Therapy and Clinical Outcomes
3
Emerging Data from the DESTINY-Breast Trials Signal Shift in Standards of Care for HER2-Positive Breast Cancer
4
FDA Approves Gepotidacin for Urogenital Gonorrhea in Adult and Pediatric Patients
5
